Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Steve Flamm"'
Publikováno v:
In Hepatology 2001 34(4) Part 2:A686-A686
Autor:
Michael Charlton, Gregory T. Everson, Steven L. Flamm, Princy Kumar, Charles Landis, Robert S. Brown, Michael W. Fried, Norah A. Terrault, Jacqueline G. O'Leary, Hugo E. Vargas, Alexander Kuo, Eugene Schiff, Mark S. Sulkowski, Richard Gilroy, Kymberly D. Watt, Kimberly Brown, Paul Kwo, Surakit Pungpapong, Kevin M. Korenblat, Andrew J. Muir, Lewis Teperman, Robert J. Fontana, Jill Denning, Sarah Arterburn, Hadas Dvory-Sobol, Theo Brandt-Sarif, Phillip S. Pang, John G. McHutchison, K. Rajender Reddy, Nezam Afdhal, Michael Fried, Kris Kowdley, Norah Terrault, Steve Flamm, John Lake, Greg Everson, Mark Sulkowski, Michael Curry, Rajender Reddy, Hugo Vargas, Andrew Muir, Atif Zaman, Robert Fontana, Jacqueline O'Leary, Obaid Shaikh, Kevin Korenblat, Richard Stravitz, Kymberly Watt, Narayanan Menon, James Bredfeldt, Carlos Romero-Marrero
Publikováno v:
Gastroenterology. 149(3):649-659
Background & Aims There are no effective and safe treatments for chronic hepatitis C virus (HCV) infection of patients who have advanced liver disease. Methods In this phase 2, open-label study, we assessed treatment with the NS5A inhibitor ledipasvi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d38f770582ba5f4fe742799ee0643a7f
Autor:
Anne Torbeyns, Misti Linaberry, Fiona McPhee, Eric Hughes, Eugene S. Swenson, Paul Y. Kwo, Steve Flamm, Mark S. Sulkowski, Zeid Kayali, Eric Lawitz, Philip D. Yin
Publikováno v:
Liver international : official journal of the International Association for the Study of the Liver. 37(6)
Background & Aims The phase 2, FOURward study (NCT02175966) investigated short-duration therapy (4/6 weeks) with four direct-acting antivirals (DAAs) with distinct mechanisms of action in patients infected with hepatitis C virus (HCV) genotype-1. Met
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff36128cd5d6cdb50e017d6297c2dcff
https://pubmed.ncbi.nlm.nih.gov/27943563
https://pubmed.ncbi.nlm.nih.gov/27943563
Autor:
Steve Flamm, Michael P. Curry, Michael S. Hughes, Elliot B. Tapper, Maria Buti, Saima Firdoos, Nezam H. Afdhal, Jean-François Dufour
Publikováno v:
Tapper, Elliot B; Hughes, Michael S; Buti, Maria; Dufour, Jean-François; Flamm, Steve; Firdoos, Saima; Curry, Michael P; Afdhal, Nezam H (2017). The optimal timing of hepatitis C therapy in transplant eligible patients with Child B and C Cirrhosis: A Cost-Effectiveness Analysis. Transplantation, 101(5), pp. 987-995. Lippincott Williams & Wilkins 10.1097/TP.0000000000001400
BACKGROUND Ledipasvir/sofosbuvir (LDV/SOF) has demonstrated high efficacy, safety and tolerability in HCV-infected patients. There is limited data, however, regarding the optimal timing of therapy in the context of possible liver transplantation (LT)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35891e65a1f6fd41c6ebd63f147d82bc
https://pubmed.ncbi.nlm.nih.gov/27495755
https://pubmed.ncbi.nlm.nih.gov/27495755
Autor:
Sulkowski, Mark S.1 msulkowski@jhmi.edu, Flamm, Steve2, Kayali, Zeid3, Lawitz, Eric J.4, Kwo, Paul5, McPhee, Fiona6, Torbeyns, Anne7, Hughes, Eric A.8, Swenson, Eugene S.6, Yin, Philip D.6, Linaberry, Misti8
Publikováno v:
Liver International. Jun2017, Vol. 37 Issue 6, p836-842. 7p.
Publikováno v:
Formulary; Jul2004, Vol. 39 Issue 7, p343-344, 2p
Autor:
Hayes, Peter, Plevris, John
Publikováno v:
European Journal of Gastroenterology & Hepatology; Nov2015, Vol. 27 Issue 11, p1357-1360, 4p
Publikováno v:
Fair Disclosure Wire (Quarterly Earnings Reports). 02/15/2018.
Publikováno v:
Fair Disclosure Wire (Quarterly Earnings Reports). 11/07/2017.
Publikováno v:
Formulary. Jul2004, Vol. 39 Issue 7, p343-343. 2/3p.